Arovella Doses First Patient In ALA-101 Cancer Trial
Arovella Therapeutics has dosed the first patient in its Phase 1 trial of ALA-101, an off-the-shelf cell therapy being evaluated in people with relapsed or refractory CD19-positive blood cancers. The study will assess safety and early signs of activity, with initial data expected early next year.
Closing price · 2026-10-27: $0.050 · +2.04%